Literature DB >> 23642696

Regorafenib for metastatic colorectal cancer.

Riccardo Ricotta, Andrea Sartore-Bianchi, Antonella Verrioli, Angelo Vanzulli, Salvatore Siena.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23642696     DOI： 10.1016/S0140-6736(13)60976-9

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  10 in total

1.  Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis.

Authors:  Dongshi Chen; Liang Wei; Jian Yu; Lin Zhang
Journal:  Clin Cancer Res       Date:  2014-04-24       Impact factor: 12.531

2.  Response to regorafenib at an initial dose of 120 mg as salvage therapy for metastatic colorectal cancer.

Authors:  Hiroshi Osawa
Journal:  Mol Clin Oncol       Date:  2017-01-31

3.  Mcl-1 Degradation Is Required for Targeted Therapeutics to Eradicate Colon Cancer Cells.

Authors:  Jingshan Tong; Peng Wang; Shuai Tan; Dongshi Chen; Zaneta Nikolovska-Coleska; Fangdong Zou; Jian Yu; Lin Zhang
Journal:  Cancer Res       Date:  2017-02-15       Impact factor: 13.312

4.  Early tumor cavitation with regorafenib in metastatic colorectal cancer: A case report.

Authors:  Kenta Kawasaki; Yasuo Hamamoto; Masayuki Adachi; Takanori Kanai; Hiromasa Takaishi
Journal:  Oncol Lett       Date:  2015-11-10       Impact factor: 2.967

5.  Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study).

Authors:  Riccardo Ricotta; Antonella Verrioli; Silvia Ghezzi; Luca Porcu; A Grothey; Alfredo Falcone; Eric Van Cutsem; Guillem Argilés; Antoine Adenis; Marc Ychou; Carlo Barone; Olivier Bouché; Marc Peeters; Yves Humblet; Laurent Mineur; Alberto F Sobrero; Joleen M Hubbard; Chiara Cremolini; Hans Prenen; Josep Tabernero; Hajer Jarraya; Thibault Mazard; Sophie Deguelte-Lardiere; Konstantinos Papadimitriou; Marc Van den Eynde; Alessandro Pastorino; Daniela Redaelli; Katia Bencardino; Chiara Funaioli; Alessio Amatu; Giulia Carlo-Stella; Valter Torri; Andrea Sartore-Bianchi; Angelo Vanzulli; Salvatore Siena
Journal:  ESMO Open       Date:  2017-02-13

Review 6.  Evolution of regorafenib from bench to bedside in colorectal cancer: Is it an attractive option or merely a "me too" drug?

Authors:  Gaurav Goel
Journal:  Cancer Manag Res       Date:  2018-03-06       Impact factor: 3.989

7.  Early morphological change for predicting outcome in metastatic colorectal cancer after regorafenib.

Authors:  Hiroyuki Arai; Kunihisa Miyakawa; Tadamichi Denda; Takuro Mizukami; Yoshiki Horie; Naoki Izawa; Mami Hirakawa; Takashi Ogura; Takashi Tsuda; Yu Sunakawa; Takako Eguchi Nakajima
Journal:  Oncotarget       Date:  2017-11-30

Review 8.  Safety and Tolerability of Anti-Angiogenic Protein Kinase Inhibitors and Vascular-Disrupting Agents in Cancer: Focus on Gastrointestinal Malignancies.

Authors:  Letizia Procaccio; Vera Damuzzo; Francesca Di Sarra; Alberto Russi; Federica Todino; Vincenzo Dadduzio; Francesca Bergamo; Alessandra Anna Prete; Sara Lonardi; Hans Prenen; Angelo Claudio Palozzo; Fotios Loupakis
Journal:  Drug Saf       Date:  2019-02       Impact factor: 5.228

Review 9.  Proactive strategies for regorafenib in metastatic colorectal cancer: implications for optimal patient management.

Authors:  Gazala Khan; Rebecca A Moss; Fadi Braiteh; Marc Saltzman
Journal:  Cancer Manag Res       Date:  2014-03-04       Impact factor: 3.989

10.  Clinical Implication of Anti-Angiogenic Effect of Regorafenib in Metastatic Colorectal Cancer.

Authors:  Yoojoo Lim; Sae-Won Han; Jeong Hee Yoon; Jeong Min Lee; Jung Min Lee; Jin Chul Paeng; Jae-Kyung Won; Gyeong Hoon Kang; Seung-Yong Jeong; Kyu Joo Park; Kyung-Hun Lee; Jee Hyun Kim; Tae-You Kim
Journal:  PLoS One       Date:  2015-12-15       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.